Clinical Trial

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 28, 2025 (before its estimated May 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The study is being conducted to compare JS004 plus Toripalimab with Investigator-Selected Chemotherapy in Patients with PD-(L)1 monoclonal antibody refractory Classic Hodgkin Lymphoma (cHL)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-12-06; most recent amendment 2025-02-26.
Status change: Not Yet Recruiting → Recruiting 2024-01-23
Trial Details
NCT Number NCT06170489
Lead Sponsor Shanghai Junshi Bioscience Co., Ltd.
Conditions Hodgkin Lymphoma
Enrollment 185 participants
Start Date 2023-12-28
Primary Completion 2025-05-31 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-28